Indian Biotech R&D Facility MEP — BSL-2/3 + WHO BMBL + DBT-RCGM + GLP + ISO 17025
An 8000 m² Indian biotech R&D facility (BSL-2 + BSL-3 + ABSL-2) demands ₹627 Cr MEP capex with BSL containment + animal house + flow cytometry + ISO 7 cell-therapy cleanroom + liquid N2 + LIMS + LEV chemical hoods. WHO BMBL + DBT-RCGM + ICMR + GLP + ISO 17025 + USFDA cGLP + ISO 14644 govern. Three failures: BSL-3 negative pressure cascade validated only at installation not annually (containment drift), animal house static cages without IVC + scavenging, cell-therapy Class A LAF without continuous monitoring.
Indian biotech R&D facility framework
India biotech R&D — DBT-funded autonomous institutes (NII + ICGEB + ILS + RGCB + InStem + THSTI), private (Bharat Biotech R&D + Biocon Park + Dr Reddys + Sun Pharma R&D + Glenmark + Strides + JBL + Premier Lab India) + CROs (Syngene + Anthem + Sai Life). Standards stack — BSL-2 + BSL-3 biocontainment per WHO BMBL + CDC + DBT-RCGM + ICMR + DSIR + GLP (Good Laboratory Practice) + ISO 17025 + USFDA cGLP + EU EMA GLP. Biotech R&D MEP signature: BSL containment + flow-cytometry + sterile cell culture + LIMS integration.
Mid-size BSL-2 + BSL-3 biotech R&D facility MEP scope — 8000 m²
| Zone | Containment | Air change | ΔP (Pa) | Capex (₹ Cr) |
|---|---|---|---|---|
| BSL-2 cell culture | BSL-2 | 12 ACH | +15 vs corridor | 85 |
| BSL-3 high-containment | BSL-3 | 12 ACH HEPA fixed | -50 (negative) | 125 |
| Animal house (rodent + non-rodent) | ABSL-2 | 15 ACH | -25 + air-lock | 85 |
| Flow cytometry + imaging | sterile | 12 ACH | +15 | 45 |
| Microbiology + bacteriology | BSL-2 | 12 ACH HEPA | -25 | 35 |
| Molecular biology + sequencing (NGS) | BSL-2 | 12 ACH | -5 | 35 |
| Bioinformatics + LIMS server room | — | — | — | 25 |
| Cleanroom (ISO 7) for cell-therapy R&D | — | 25 ACH HEPA | +15 | 85 |
| Liquid N2 + cryogenic storage | — | — | — | 25 |
| Autoclave + decontamination | — | — | — | 25 |
| Chemical hood + fume cupboard | LEV | 25 ACH | -15 | 22 |
| Waste handling (autoclave + incinerate) | BMW | — | — | 35 |
| Total biotech R&D | — | — | — | 627 |
Three Indian biotech R&D MEP failures
- BSL-3 negative pressure cascade not validated — BSL-3 requires -50 Pa to corridor + -75 Pa anteroom cascade. WHO BMBL + CDC require continuous monitoring + alarm. Indian sites often validate at installation but not recommissioned annually — drift causes containment breach risk.
- Animal house IVC + scavenging — IVC (Individually Ventilated Cage) at 60-70 ACH inside rack. Ammonia + allergen scavenging from cage exhaust requires HEPA + activated carbon. Indian animal houses sometimes use static cages — animal welfare + reproducibility issues.
- Cell-therapy cleanroom Class A LAF without environmental monitoring — ISO 14644 + USFDA 21 CFR 211 require continuous viable + non-viable particle monitoring at critical-zone Class A. Indian R&D often skip — fails clinical translation regulatory.
- WHO BMBL Biosafety in Microbiological + Biomedical Laboratories 6th Edition 2020.
- CDC + NIH Guidelines for Research Involving Recombinant DNA 2024.
- DBT-RCGM Department of Biotechnology India Recombinant DNA Guidelines 2024.
- ICMR Indian Council of Medical Research Biosafety Guidelines 2024.
- GLP Good Laboratory Practice OECD 1997 + India National GLP Compliance Monitoring Authority NGCMA 2024.
- ISO 17025:2017 — Laboratory Quality.
- USFDA 21 CFR 58 cGLP + ICH Q9.
- ISO 14644 + USP 1116 — Cleanroom + Microbiological Monitoring.